Meryk A, Grasse M, Balasco L, Kapferer W, Grubeck Loebenstein B, Pangrazzi L. Antioxidants N-Acetylcysteine and Vitamin C Improve T Cell Commitment to Memory and Long-Term Maintenance of Immunological Memory in Old Mice. Antioxidants (Basel). 2020;9: pubmed publisher

Scherer S, Oberle S, Kanev K, Gerullis A, Wu M, de Almeida G, et al. Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development. Nat Immunol. 2023;24:501-515 pubmed publisher

Eschweiler S, Wang A, Ram xed rez Su xe1 stegui C, von Witzleben A, Li Y, Chee S, et al. JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells. Cell Rep. 2023;42:112040 pubmed publisher

Lin Y, Duong H, Limary A, Kim E, Hsu P, Patel S, et al. Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity. 2023;56:207-223.e8 pubmed publisher

Hu J, He J, Wang Y, Zhao Y, Fang K, Dong Y, et al. Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy. J Immunother Cancer. 2022;10: pubmed publisher

Delacher M, Simon M, Sanderink L, Hotz Wagenblatt A, Wuttke M, Schambeck K, et al. Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. Immunity. 2021;54:702-720.e17 pubmed publisher

Levin M, Kroehl M, Johnson M, Hammes A, Reinhold D, Lang N, et al. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018;128:4429-4440 pubmed publisher

Wang D, Diao H, Getzler A, Rogal W, Frederick M, Milner J, et al. The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. Immunity. 2018;48:659-674.e6 pubmed publisher

Herndler Brandstetter D, Ishigame H, Shinnakasu R, Plajer V, Stecher C, Zhao J, et al. KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity. 2018;48:716-729.e8 pubmed publisher

Akhmetzyanova I, Zelinskyy G, Littwitz Salomon E, Malyshkina A, Dietze K, Streeck H, et al. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity. J Immunol. 2016;196:484-92 pubmed publisher